Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a new CT scan spot tiny gut lesions that older scans miss?

NCT ID NCT07748923

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This trial compares two types of CT scans—photon-counting CT (PCCT) and dual-energy CT (DECT)—to see which one is better at finding small gastrointestinal lesions (like tiny growths or thickening in the gut lining). About 1,700 adults who are having a contrast-enhanced abdominal CT and have at least one suspected or confirmed small lesion will be included. The study will check how often each scan detects these lesions, using endoscopy with biopsy as the gold standard, and also look at image quality and how well different doctors agree on what they see.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Contrast-enhanced photon-counting computed tomography (PCCT) compared with energy-integrating detector dual-energy CT (DECT)
What this could lead to
If PCCT proves more accurate, it could become the preferred imaging method for detecting small gastrointestinal lesions, potentially reducing missed diagnoses and the need for invasive procedures.
What could go wrong
The trial is a comparison study, not a treatment trial, so it won't directly improve outcomes. PCCT may not show a significant advantage over DECT, and its higher cost or limited availability could limit widespread adoption.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,762 people

The number who actually took part.

Started

Sep 2023

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study includes two cohorts: a retrospective diagnostic-performance cohort and a prospective clinical implementation cohort. Patients underwent contrast-enhanced photon-counting CT (PCCT) or energy-integrating detector dual-energy CT (DECT) for evaluation of suspected small gastrointestinal lesions in a clinical setting.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged 18-80 years. 2. Patients undergoing contrast-enhanced abdominal CT (photon-counting CT or energy-integrating detector dual-energy CT). 3. At least one endoscopically detected or clinically suspected small gastrointestinal lesion. 4. Lesions confirmed or suspected on endoscopy, pathology, or follow-up imaging. 5. Lesions characterized as mucosal thickening or nodular lesions within predefined size criteria (≤2 cm). Exclusion Criteria: 1. Prior gastrointestinal surgery affecting target evaluation region. 2. Poor or nondiagnostic CT image quality. 3. Incomplete or unavailable endoscopic or histopathological reference standard. 4. Ambiguous lesion localization on endoscopy or imaging. 5. Severe motion artifacts or inadequate bowel distension affecting diagnostic evaluation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastrointestinal lesions are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, 400010, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.